Search

The article enhances nurses' understanding of the role of genomics in nursing practice and explains its benefits in healthcare practice. Topics discussed are benefits of pharmacogenomics relating to the liver enzyme CYP2D6 which is a part of the cytochrome P450 2D6 family, genomics infrastructure, the need to educate nurses and support the development of knowledge and skills related to genomics, ethical aspects of genomics and prenatal screening for genetic conditions.

The article discusses the recommendation by researchers that guidelines set by the Royal College of Obstetrics and Gynaecologists concerning miscarriage should be updated to include a criteria for a repeat scan to avoid the risk of misdiagnosis and termination of viable pregnancies.

This section reports on the launch of healthcare services including the TeenageCancer Trust's nursing and support services in Scotland, the National Institute for Health and Care Excellence's guideline on road crossings, and a safe test for Down's syndrome for pregnant women in Wales.

The author considers antenatal screening for Down's syndrome and the sensitive cell-free DNA screening called non-invasive prenatal testing (NIPT) as having the right to individual informed choice. She points out the problem with the hypothesis of the NIPT program regarding a woman's choice to terminate her pregnancy and the potential implication of her decision for the Down's syndrome community. She stresses the role health professionals in caring and providing support for pregnant women.

The article focuses on the acquisition of Ariosa Diagnostics, molecular diagnostics testing services provider, by health-care company Roche and the acquisition will focus on noninvasive prenatal testing (NIPT).

The article informs that an American integrated systems manufacturer Illumina has signed a deal with China's Berry Genomics to expand its next-generation sequencing technology for noninvasive prenatal testing in overseas market.